![]() |
|
|
Cereal Research Centre, Agriculture and Agri-Food Canada, Winnipeg, Manitoba R3T 2M9, Canada
* To whom correspondence should be addressed. E-mail: names{at}agr.gc.ca.
Government-approved health claims support dietary intervention as a safe and practical approach to improving consumer health and provide industry with regulatory guidelines for food product labels. Claims already allowed in the United States, United Kingdom, Sweden, and The Netherlands for reducing cholesterol through consumption of oat or barley soluble fiber provide a basis for review, but each country may have different criteria for assessing clinical evidence for a physiological effect. For example, the FDA-approved barley health claim was based on a petition that included 39 animal model studies and 11 human clinical trials. Since then, more studies have been published, but with few exceptions, clinical data continue to demonstrate that the consumption of barley products is effective for lowering total and LDL cholesterol. More research is needed to fully understand the mechanism of cholesterol reduction and the role of β-glucan molecular weight, viscosity, and solubility. In an assessment of the physiological efficacy of a dietary intervention, consideration should also be given to the potential impact of physical and thermal food-processing treatments and genotypic variation in the barley source. New barley cultivars have been generated specifically for food use, possessing increased β-glucan, desirable starch composition profiles, and improved milling/processing traits. These advances in barley production, coupled with the establishment of a government-regulated health claim for barley β-glucan, will stimulate new processing opportunities for barley foods and provide consumers with reliable, healthy food choices.
This article has been cited by other articles:
![]() |
P. J. H. Jones, N.-G. Asp, and P. Silva Proceedings of a symposium held at the Canadian Nutrition Congress. June 21, 2007. Winnipeg, Canada. J. Nutr., June 1, 2008; 138(6): 1189S - 1260S. [Full Text] [PDF] |
||||
![]() |
K. Yamada, N. Sato-Mito, J. Nagata, and K. Umegaki Health Claim Evidence Requirements in Japan J. Nutr., June 1, 2008; 138(6): 1192S - 1198S. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Yang Scientific Substantiation of Functional Food Health Claims in China J. Nutr., June 1, 2008; 138(6): 1199S - 1205S. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. C. Tapsell Evidence for Health Claims: A Perspective from the Australia-New Zealand Region J. Nutr., June 1, 2008; 138(6): 1206S - 1209S. [Abstract] [Full Text] [PDF] |
||||
![]() |
N.-G. Asp and S. Bryngelsson Health Claims in Europe: New Legislation and PASSCLAIM for Substantiation J. Nutr., June 1, 2008; 138(6): 1210S - 1215S. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. M. Hasler Health Claims in the United States: An Aid to the Public or a Source of Confusion? J. Nutr., June 1, 2008; 138(6): 1216S - 1220S. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. R. L'Abbe, L. Dumais, E. Chao, and B. Junkins Health Claims on Foods in Canada J. Nutr., June 1, 2008; 138(6): 1221S - 1227S. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Jew, C. A. Vanstone, J.-M. Antoine, and P. J. H. Jones Generic and Product-Specific Health Claim Processes for Functional Foods across Global Jurisdictions J. Nutr., June 1, 2008; 138(6): 1228S - 1236S. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. W. Xiao Health Effects of Soy Protein and Isoflavones in Humans J. Nutr., June 1, 2008; 138(6): 1244S - 1249S. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. R. Farnworth The Evidence to Support Health Claims for Probiotics J. Nutr., June 1, 2008; 138(6): 1250S - 1254S. [Abstract] [Full Text] [PDF] |
||||